State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee

Ryan, C. E.; Ahn, I. E.; Sekar, A.; Rawstron, A.; Almeida, J.; Martin-Subero, I.; Parry, E. M.; Alcoceba, M.; Calado, D. P.; Orfao, A.; Langerak, A. W.; Veelken, H.; Langerbeins, P.; Stephens, D. M.; Parikh, S. A.; Niemann, C. U.; Roulland, S.; Stamatopoulos, K.; Slager, S. L.; Shanafelt, T.; Ghia, P.; Okosun, J.; Davids, M. S.

doi:10.1038/s41408-025-01341-6

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee / Ryan, C. E.; Ahn, I. E.; Sekar, A.; Rawstron, A.; Almeida, J.; Martin-Subero, I.; Parry, E. M.; Alcoceba, M.; Calado, D. P.; Orfao, A.; Langerak, A. W.; Veelken, H.; Langerbeins, P.; Stephens, D. M.; Parikh, S. A.; Niemann, C. U.; Roulland, S.; Stamatopoulos, K.; Slager, S. L.; Shanafelt, T.; Ghia, P.; Okosun, J.; Davids, M. S.. - In: BLOOD CANCER JOURNAL. - ISSN 2044-5385. - 15:1(2025). [10.1038/s41408-025-01341-6]